Guardian Pharmacy Services (NYSE:GRDN) Director Thomas Salentine Jr Sells 3,570,677 Shares of Stock

Key Points

• Director Thomas Salentine Jr. sold 3,570,677 shares on March 20 at an average price of $29.68, raising about $105.98 million and cutting his stake by 44.41% to 4,469,316 shares, according to the SEC filing.
• Guardian beat quarterly expectations on March 11 with EPS of $0.37 (vs. $0.27 est.) and revenue of $397.6M, up 17.4% year-over-year, while the stock recently traded near $37.58 and the company has a $2.38B market cap.
• Analyst sentiment is broadly positive—MarketBeat shows an average "Buy" rating with a consensus price target of $38.00, and multiple firms (Oppenheimer, Raymond James, UBS) have issued buy/outperform ratings or raised targets.

Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) Director Thomas Salentine, Jr. sold 3,570,677 shares of the business's stock in a transaction on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $105,977,693.36. Following the completion of the sale, the director directly owned 4,469,316 shares in the company, valued at approximately $132,649,298.88. This represents a 44.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Guardian Pharmacy Services Trading Up 0.9%

GRDN stock opened at $37.58 on Wednesday. Guardian Pharmacy Services, Inc. has a 1-year low of $19.17 and a 1-year high of $38.12. The firm has a market capitalization of $2.38 billion, a PE ratio of 48.81 and a beta of 0.86. The business's 50 day simple moving average is $32.49 and its 200 day simple moving average is $29.83.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.10. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The business had revenue of $397.62 million for the quarter, compared to analyst estimates of $390.04 million. Guardian Pharmacy Services's quarterly revenue was up 17.4% on a year-over-year basis. As a group, sell-side analysts predict that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Guardian Pharmacy Services in the 1st quarter worth $233,000. Envestnet Asset Management Inc. grew its position in shares of Guardian Pharmacy Services by 7.1% during the second quarter. Envestnet Asset Management Inc. now owns 12,126 shares of the company's stock valued at $258,000 after purchasing an additional 805 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Guardian Pharmacy Services by 65.9% during the 2nd quarter. Geode Capital Management LLC now owns 336,701 shares of the company's stock worth $7,177,000 after acquiring an additional 133,715 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Guardian Pharmacy Services by 76.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company's stock valued at $52,000 after purchasing an additional 1,062 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Guardian Pharmacy Services in the 2nd quarter worth about $346,000.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Zacks Research upgraded shares of Guardian Pharmacy Services from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, March 18th. Oppenheimer raised their target price on Guardian Pharmacy Services from $35.00 to $38.00 and gave the company an "outperform" rating in a research report on Thursday, March 12th. Raymond James Financial reissued an "outperform" rating and set a $40.00 price objective on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Guardian Pharmacy Services in a research note on Monday, December 29th. Finally, UBS Group reissued a "buy" rating on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $38.00.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.